Last updated: July 11, 2026

Application No. 19/408,114

Untitled Application

Unknown

Filed

1600

Priority

Mar 26, 2020 — provisional 63/000,464 +4 more

Examiner

SPENCE, JENNIFER SUZANNE

Art Unit

1633

Tech Center

Genentech, Inc.

Assignee

Genentech Inc.

OA Round

1 (Non-Final)

Interview Optional

— +49.5% interview lift. Examiner has a relatively high allowance rate (66%); +49.5% interview lift. A written response may suffice.

Based on 119 resolved cases, 2023–2026

Examiner Intelligence

SPENCE, JENNIFER SUZANNE View full profile →

Grants 66% — above average

Career Allowance Rate

78 granted / 119 resolved

+5.5% vs TC avg

Strong +50% interview lift

Without

With

+49.5%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

44 currently pending

Career history

172

Total Applications

across all art units

Statute-Specific Performance

§101

0.2%

-39.8% vs TC avg

§103

74.5%

+34.5% vs TC avg

§102

2.2%

-37.8% vs TC avg

§112

3.6%

-36.4% vs TC avg

Black line = Tech Center average estimate • Based on career data from 119 resolved cases

Prosecution Timeline

1600

Application Filed

Apr 29, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

17/599,831

Patent 12653842

Treatment Of Intervertebral Disc Degeneration

4y 8m to grant Granted Jun 16, 2026

17/917,770

Patent 12649932

ENHANCED VIRAL TRANSDUCTION OF MAMMALIAN CELLS USING MATERIAL SCAFFOLDS

3y 8m to grant Granted Jun 09, 2026

17/430,676

Patent 12600971

MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE

4y 8m to grant Granted Apr 14, 2026

17/925,411

Patent 12594302

Single Domain Antibodies and Their Use in Cancer Therapies

3y 4m to grant Granted Apr 07, 2026

17/649,305

Patent 12577283

KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS

4y 1m to grant Granted Mar 17, 2026

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

66%

Grant Probability

99%

With Interview (+49.5%)

3y 7m

Median Time to Grant

Low

PTA Risk

Based on 119 resolved cases by this examiner. Grant probability derived from career allowance rate.